A5053732763- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Diet and metabolism studies
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Dietary Effects on Health
- Inflammatory Biomarkers in Disease Prognosis
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Cancer Risks and Factors
- Drug Transport and Resistance Mechanisms
- Metabolism, Diabetes, and Cancer
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Ovarian cancer diagnosis and treatment
- Cancer-related cognitive impairment studies
Fondazione IRCCS Istituto Nazionale dei Tumori
2021-2025
University of Milan
2022-2025
Dana-Farber Cancer Institute
2025
Harvard University
2025
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 evaluated, HER2-low was independently associated significantly worse PFS and OS when compared HER2-0 status. Based on our findings, could become a new biomarker this clinical setting.
Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents is the standard first-line treatment for patients hormone receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer. However, optimal after tumor progression to ET plus CDK4/6i remains unclear. To evaluate progression-free survival (PFS) and overall (OS) in clinical practice setting ERBB2-negative cancer following CDK4/6i. The multicenter retrospective cohort study...
Several uncommon genomic alterations beyond RAS and BRAFV600E mutations drive primary resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC). Our PRESSING panel (including PIK3CA exon 20/AKT1/PTEN mutations, ERBB2/MET amplifications, gene fusions, microsatellite instability-high status) represented a paradigm of negative hyperselection with more precise tailoring EGFR blockade. However, modest proportion hyperselected mCRC has intrinsic...
Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is need to identify novel biomarkers guide future research and improve clinical outcomes.We tested the prognostic ability of an emerging, complete blood count (CBC)-based inflammatory biomarker, pan-immune-inflammation value (PIV), in patients with aTNBC treated first-line, platinum-based chemotherapy.This was retrospective, monocentric, observational study.We included consecutive platinum-based, first-line...
Abstract Background Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its routine clinical practice. In this multicenter retrospective study, we examined effectiveness and safety of T-DXd a real-world population. Methods Clinico-pathological information mBC who received were collected from 12 Italian hospitals. HER2 status was determined locally. Patients at least one...
Severe calorie restriction, in the form of cyclic fasting or fasting-mimicking diets (FMDs), boosts antitumor activity cytotoxic chemotherapy mouse models triple-negative breast cancer (TNBC). This effect is mostly mediated by fasting/FMD-induced reduction plasma glucose concentration and a boost immunity. However, clinical evidence that FMD may impact on outcomes advanced TNBC (aTNBC) patients lacking. We compared overall survival (OS) 14 aTNBC receiving first-line carboplatin-gemcitabine...
Abstract Introduction: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) are the standard first-line treatment for patients hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (HR+/HER2- aBC). HER2-low BC, which is defined by an IHC score HER2 of 1+ or 2+ negative ISH assay, accounts more than half all HR+/HER2- aBC cases, and it associated remarkable clinical benefit from novel anti-HER2...
Abstract Isocitrate dehydrogenase ( IDH ) 1/2 mutations are the most frequent druggable alterations in intrahepatic cholangiocarcinoma (iCCA), reported ~20% of cases. Preclinical evidence indicates that these associated with homologous recombination deficiency (HRD), which could be exploited as a target for platinum chemotherapy (ChT) and PARP inhibitors. However, role IDH1/2 surrogate biomarkers efficacy is unknown. We conducted multicenter, propensity score‐matched analysis to investigate...
Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2- aBC).
TPS3639 Background: Robust clinical activity has been observed with anti–PD-1 pembrolizumab (pembro) in patients (pts) dMMR/MSI-H metastatic CRC tumors. However, given the response rate of 45% first-line pembro demonstrated KEYNOTE-177, there is room for improvement. Adding a second checkpoint inhibitor targeting different pathway such as CTLA-4, LAG-3, TIGIT, or ILT4 may improve efficacy PD-1 inhibition. This ongoing, open-label, multicenter, multiarm, randomized, phase 2 trial...
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the established first-line (1L) for patients (pts) hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC). Data supporting best treatment choice at progression on CDK4/6i+ET is limited. We collected data from pts HR+/HER2- mBC who received after to in five Italian Institutions. Progression-free survival 2 (PFS2), primary endpoint, was calculated initiation of CDK4/6i disease (PD) subsequent...
Patients (pts) with germinal BRCA mutated (gBRCAm) breast cancer (BC) have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP-inhibitors (PARPi). As reported in ovarian cancer, resistance these treatments partially overlap. In gBRCAm BC, it is unclear if prior exposure PARPi/PBC affects tumor response subsequent PBC/PARPi. We conducted a retrospective, multicentre observational study assess the benefit of PARPi post-PBC viceversa pts BC. Pts included received:...
e16179 Background: Biliary tract cancers (BTCs) are a group of rare tumors with dismal prognosis and complex molecular landscape. In this setting, the incidence clinical relevance cancer-associated thrombosis (CAT) is unknown, thus BTCs not included in common thrombotic risk scores (e.g. Khorana Score). Moreover, retrospective studies highlighted associations between thromboembolic events some genetic alterations, such as KRAS lung colorectal cancer, ALK/ROS1 cancer IDH1 mutations glioma....
Abstract Background: Several genomic alterations beyond RAS and BRAFV600E mutations have been preclinically validated as primary resistance drivers to EGFR inhibition in mCRC. We showed that our PRESSING panel (including PIK3CA exon 20/AKT1/PTEN mutations, ERBB2/MET amplification ALK/ROS1/RET/NTRKs fusions) is useful promote a new paradigm of negative hyper-selection, since patients with RAS/BRAF wt MSS mCRC achieve significantly worse survival upon anti-EGFRs. With the aim further refining...
Cholangiocarcinoma (CCA) is a malignant disease of the biliary tree which accounts for 15% primary liver cancers and 3% gastrointestinal malignancies.For almost decade, palliative chemotherapy remained standard care advanced CCA with only modest control survival rates, both in first-and second-line settings.In recent years, thanks to advances next-generation sequencing (NGS), an extensive range targetable genetic alterations has been identified.In this review, we highlight different driver...